PDMR Dealing
13/05/2026 10:52
RNS Number : 1742E Oxford Biomedica PLC 13 May 2026 PDMR Dealing Oxford, UK - 13 May 2026: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, today announces that Natalie Walter, Chief Legal Officer and Group Company Secretary has exercised 3,057 Save As You Earn (SAYE) 2022 options at an exercise price of £2.944 per share on 12 May 2026 and disposed of 3,057 shares at an average price of £6.3939 per share on 12 May 2026. In addition, Lisa Doman, Chief People Officer, has exercised 10,591 Deferred Bonus Plan (DBP) options and 2,709 Executive Share Option Scheme (ESOS) options at an exercise price of £nil per share and £4.966 per share respectively on 12 May 2026 and sold 13,300 shares at an average price of £6.35 per share on 12 May 2026. The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the transaction.
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||||
| b) | Name of natural person | Natalie Walter | ||||||
| c) | Legal person | |||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||
| 3. | Details of the Issuer | |||||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Date of the transaction | 12 May 2026 | ||||||
| b) | Description of the financial instrument | Share | ||||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||||
| d) | Nature of the transaction | Exercise of SAYE 2022 Options | ||||||
| e) | Place of the transaction | Outside the trading venue | ||||||
| f) | Currency | GBP - British pound | ||||||
| g) | Price(s) and volumes(s) |
| ||||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £2.944 £8,999.81 | ||||||
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||
| b) | Name of natural person | Natalie Walter | ||||
| c) | Legal person | |||||
| 2. | Reason for the notification | |||||
| a) | Position/status | Chief Legal Officer and Group Company Secretary | ||||
| b) | Initial notification/ amendment | Initial Notification | ||||
| 3. | Details of the Issuer | |||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Date of the transaction | 12 May 2026 | ||||
| b) | Description of the financial instrument | Share | ||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||
| d) | Nature of the transaction | Sale of shares | ||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
| f) | Currency | GBP - British pound | ||||
| g) | Price(s) and volumes(s) |
| ||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 3,057 £6.3939 £19,546.15 | ||||
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||||
| b) | Name of natural person | Lisa Doman | ||||||
| c) | Legal person | |||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status | Chief People Officer | ||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||
| 3. | Details of the Issuer | |||||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Date of the transaction | 12 May 2026 | ||||||
| b) | Description of the financial instrument | Share | ||||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||||
| d) | Nature of the transaction | Exercise of DBP options | ||||||
| e) | Place of the transaction | Outside the trading venue | ||||||
| f) | Currency | GBP - British pound | ||||||
| g) | Price(s) and volumes(s) |
| ||||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 10,591 £nil £nil | ||||||
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||||
| b) | Name of natural person | Lisa Doman | ||||||
| c) | Legal person | |||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status | Chief People Officer | ||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||
| 3. | Details of the Issuer | |||||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Date of the transaction | 12 May 2026 | ||||||
| b) | Description of the financial instrument | Share | ||||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||||
| d) | Nature of the transaction | Exercise of ESOS Options | ||||||
| e) | Place of the transaction | Outside the trading venue | ||||||
| f) | Currency | GBP - British pound | ||||||
| g) | Price(s) and volumes(s) |
| ||||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 2,709 £4.966 £13,452.89 | ||||||
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated with them ("PCA") | |||||||
| a) | Is this a PDMR or PCA submission | Submission for PDMR | ||||||
| b) | Name of natural person | Lisa Doman | ||||||
| c) | Legal person | |||||||
| 2. | Reason for the notification | |||||||
| a) | Position/status | Chief People Officer | ||||||
| b) | Initial notification/ amendment | Initial Notification | ||||||
| 3. | Details of the Issuer | |||||||
| a) | Full name of the entity | Oxford Biomedica plc | ||||||
| b) | LEI code | 213800S1GVQNXQ15K851 | ||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Date of the transaction | 12 May 2026 | ||||||
| b) | Description of the financial instrument | Share | ||||||
| c) | Identification code | ISIN: GB00BDFBVT43 | ||||||
| d) | Nature of the transaction | Sale of Shares | ||||||
| e) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||||
| f) | Currency | GBP - British pound | ||||||
| g) | Price(s) and volumes(s) |
| ||||||
| h) | Aggregated information - Aggregate volume - Price - Aggregated total | 13,300 £6.35 £84,455.00 | ||||||